Issue 1 | Sharing of CAR Positive Rate Testing Data
Release Date:
2023-09-21 13:39
China’s First Launch—New Tool for Detecting CAR Positive Rate
In 2010, two patients with hematologic malignancies became the first participants in a clinical trial of CAR-T cell therapy at the Perelman School of Medicine at the University of Pennsylvania, and their cancers achieved complete remission that same year. More than a decade later, research published in Nature and based on up to 10 years of follow-up data indicate that CAR-T cells can still be detected in patients’ bodies 10 years after infusion. Owing to their high selectivity, localized high concentrations, and customizable nature, cell therapies have ushered in a new chapter in cancer immunotherapy.
CAR-T Cell Expansion and Persistence in Two Patients
Data sources: Nature, Zhiyin Global Biopharmaceutical Project Database
The manufacturing process for CAR-X cell therapies is complex and involves numerous quality-control steps. As an essential component of quality assurance for CAR-X therapy, the assay for detecting the positive expression rate of CAR-X currently lacks a standardized protocol. The Anti-(G4S)n (B02H1) monoclonal antibody, a broadly applicable CAR detection reagent, can directly identify and confirm the presence of CAR regardless of its antigen specificity. By recognizing the flexible (G4S)n linker, this antibody can bind to CARs with diverse specificities expressed on the cell surface; these CARs all contain a (G4S)n spacer (n ≥ 2) in their extracellular scFv domain.
We thank our customers for their support of our new products and for working with us to explore and validate innovative approaches that can replace conventional testing methods. Whether in preclinical or clinical settings, our customers have promptly shared experimental result images and provided highly positive feedback and evaluations.
Case Study on Sharing CAR Positive Rate Testing Data
The following data were kindly provided by the client. Thank you!
Data Point 1: CAR Positive Expression Rate Assay (Clinical Case)
Data Point 2: CAR Positive Expression Rate Assay (Preclinical Case)
Data Point 3: Comparative Test Chart with a Competing Foreign Brand
Trial samples are still being accepted.
Related News
HiXpan® Cell Culture Additive: Answers to Key Questions (Part 2)
Hycell’s maximum production capacity per batch is 200–400 units of the 500 mL format, ensuring stable supply and meeting customers’ ongoing production needs.
HiXpan® Cell Culture Additive: Key Questions and Answers (Part 1)
The blood‑derived raw materials used in HiXpan® cell culture additives comply with all regulatory requirements throughout collection, ethical review, informed consent, and commercial authorization, and are supported by a fully traceable supply chain.
This paper focuses on how Hycells transforms biological variability into engineering‑level determinism through a scientifically informed blending strategy and stringent control at the collection end.
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how Hycells proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board